<p>Crinetics Pharmaceuticals, Inc.（纳斯达克代码：CRNX - 免费报告）- HC Wainwright 的股票研究人员在 5 月 8 日星期五向投资者发布的研究报告中下调了 Crinetics Pharmaceuticals 的 2030 财年收益预期。HC Wainwright 分析师 D. Tsao 现在预计该公司在这一年将每股盈利 2.65 美元，低于之前预测的 2.98 美元。市场普遍预计 Crinetics Pharmaceuticals 当前全年的每股收益为（4.95 美元）。</p>
<p>Crinetics Pharmaceuticals（纳斯达克代码：CRNX - 获取免费报告）最近在 5 月 7 日星期四发布了季度财报。该公司报告季度每股收益为（1.23 美元），低于市场普遍预期的（1.22 美元）0.01 美元。Crinetics Pharmaceuticals 的股本回报率为负 43.96%，净利润率为负 2,747.18%。该公司在本季度的收入为 1,073 万美元，而市场普遍预期为 851 万美元。去年同期，该公司每股收益为（1.04 美元）。该公司的季度收入同比增长 2873.4%。</p>
<p>其他几位股票分析师也对该公司发布了报告。Wall Street Zen 在周六的研究报告中将 Crinetics Pharmaceuticals 的评级从 “卖出” 下调至 “强烈卖出”。Lifesci Capital 在 2 月 13 日星期五的研究报告中将 Crinetics Pharmaceuticals 的评级上调至 “强烈买入”。Weiss Ratings 在 4 月 20 日星期一的报告中重新发布了对 Crinetics Pharmaceuticals 股票的 “卖出（d-）” 评级。高盛集团在 1 月 12 日星期一的研究报告中将 Crinetics Pharmaceuticals 的股票评级从 “中性” 上调至 “买入”，并设定了 67.00 美元的目标价。最后，Citizens Jmp 在周五的研究报告中将 Crinetics Pharmaceuticals 的目标价从 97.00 美元下调至 95.00 美元，并对该股票设定了 “市场表现优于大盘” 的评级。一位研究分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Crinetics Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 76.50 美元。</p>
<p><strong>获取我们对 CRNX 的最新分析</strong></p>
<h2>Crinetics Pharmaceuticals 股票表现</h2>
<p>CRNX 的股票在周一开盘价为 37.48 美元。该公司的 50 日移动平均价格为 38.41 美元，200 日移动平均价格为 43.89 美元。该公司的市值为 39.5 亿美元，市盈率为 -7.31，贝塔值为 0.28。Crinetics Pharmaceuticals 的 52 周低点为 25.83 美元，52 周高点为 57.99 美元。</p>
<h2>内部人士下注</h2>
<p>在其他 Crinetics Pharmaceuticals 的新闻中，首席执行官 Richard Scott Struthers 于 3 月 16 日星期一出售了 21,981 股该股票。该股票以平均价格 37.37 美元出售，总价值为 821,429.97 美元。交易后，首席执行官持有该公司 404,778 股股票，价值约为 15,126,553.86 美元。这代表了他们持股比例的 5.15% 的减少。该交易在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。此外，内部人士 Jeff E. Knight 于 4 月 8 日星期三出售了 85,163 股该公司的股票。该股票以平均价格 40.10 美元出售，总价值为 3,415,036.30 美元。交易后，内部人士持有该公司 105,289 股股票，价值约为 4,222,088.90 美元。这笔交易代表了他们持股比例的 44.72% 的减少。该销售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内出售了价值 5,569,475 美元的 142,380 股公司股票。内部人士持有该公司 3.80% 的股票。</p>
<h2>Crinetics Pharmaceuticals 的机构交易</h2>
<p>机构投资者和对冲基金最近修改了对该股票的持有。Dimensional Fund Advisors LP 在第一季度将其在 Crinetics Pharmaceuticals 的持仓增加了 55.2%。Dimensional Fund Advisors LP 现在拥有 852,258 股该公司的股票，价值 30,935,000 美元，在此期间又收购了 303,281 股。SEB Asset Management AB 在第一季度收购了 Crinetics Pharmaceuticals 的新头寸，价值约为 7,769,000 美元。Principal Financial Group Inc. 在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 32.3%。Principal Financial Group Inc. 现在拥有 7,066 股该公司的股票，价值 257,000 美元，在上个季度又购买了 1,725 股。肯塔基州教师退休系统在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 4.0%。肯塔基州教师退休系统现在拥有 28,477 股该公司的股票，价值 1,034,000 美元，在上个季度又购买了 1,100 股。最后，Fifth Third Bancorp 在第一季度收购了 Crinetics Pharmaceuticals 的新股份，价值 126,000 美元。98.51% 的股票由机构投资者持有。</p>
<h2>关于 Crinetics Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Crinetics Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于治疗罕见内分泌疾病的新型治疗药物。该公司的专有平台利用对激素受体信号传导的洞察，设计小分子候选药物，以解决由激素活动失调引起的疾病。Crinetics 的研究工作集中在针对生长抑素、抗利尿激素和其他 GPCR 介导的通路，旨在改善患者的便利性和依从性。</p>
<p>该公司的主要产品候选药物 paltusotine（前称 CRN04777）是一种选择性非肽类生长抑素受体 2 型激动剂，正在评估用于治疗肢端肥大症和类癌综合症腹泻。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们认为比 Crinetics Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：强劲势头的 AI 相关投资机会</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后获得提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从这项重大法案中受益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Crinetics Pharmaceuticals 吗？</h2>
<p>在考虑投资 Crinetics Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Crinetics Pharmaceuticals 并不在名单上。</p>
<p>虽然 Crinetics Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CRNX

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>HC Wainwright 已经修订了 Crinetics Pharmaceuticals (NASDAQ:CRNX) 的 2030 财年盈利预期，将其从每股 2.98 美元下调至 2.65 美元。该公司当前全年的共识盈利预期为每股（4.95）美元。Crinetics 报告的季度亏损为每股（1.23）美元，略微低于预期。该公司经历了 2873.4% 的显著收入增长，同比总计 1073 万美元。分析师对该股票的评级不一，整体评级为 “适度买入”，平均目标价为 76.50 美元。内部人士最近出售了股份，显示出潜在的担忧</p>

<p>Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities researchers at HC Wainwright lowered their FY2030 earnings estimates for Crinetics Pharmaceuticals in a research note issued to investors on Friday, May 8th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $2.65 per share for the year, down from their previous forecast of $2.98. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($4.95) per share.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc.（纳斯达克代码：CRNX - 免费报告）- HC Wainwright 的股票研究人员在 5 月 8 日星期五向投资者发布的研究报告中下调了 Crinetics Pharmaceuticals 的 2030 财年收益预期。HC Wainwright 分析师 D. Tsao 现在预计该公司在这一年将每股盈利 2.65 美元，低于之前预测的 2.98 美元。市场普遍预计 Crinetics Pharmaceuticals 当前全年的每股收益为（4.95 美元）。</p>
</div><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million during the quarter, compared to the consensus estimate of $8.51 million. During the same quarter last year, the firm earned ($1.04) EPS. The business's revenue for the quarter was up 2873.4% on a year-over-year basis.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals（纳斯达克代码：CRNX - 获取免费报告）最近在 5 月 7 日星期四发布了季度财报。该公司报告季度每股收益为（1.23 美元），低于市场普遍预期的（1.22 美元）0.01 美元。Crinetics Pharmaceuticals 的股本回报率为负 43.96%，净利润率为负 2,747.18%。该公司在本季度的收入为 1,073 万美元，而市场普遍预期为 851 万美元。去年同期，该公司每股收益为（1.04 美元）。该公司的季度收入同比增长 2873.4%。</p>
</div><p>Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Crinetics Pharmaceuticals from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday. Lifesci Capital upgraded Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Friday, February 13th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a research report on Monday, January 12th. Finally, Citizens Jmp reduced their target price on shares of Crinetics Pharmaceuticals from $97.00 to $95.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Crinetics Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $76.50.</p>
<div class="lb-trans"><p>其他几位股票分析师也对该公司发布了报告。Wall Street Zen 在周六的研究报告中将 Crinetics Pharmaceuticals 的评级从 “卖出” 下调至 “强烈卖出”。Lifesci Capital 在 2 月 13 日星期五的研究报告中将 Crinetics Pharmaceuticals 的评级上调至 “强烈买入”。Weiss Ratings 在 4 月 20 日星期一的报告中重新发布了对 Crinetics Pharmaceuticals 股票的 “卖出（d-）” 评级。高盛集团在 1 月 12 日星期一的研究报告中将 Crinetics Pharmaceuticals 的股票评级从 “中性” 上调至 “买入”，并设定了 67.00 美元的目标价。最后，Citizens Jmp 在周五的研究报告中将 Crinetics Pharmaceuticals 的目标价从 97.00 美元下调至 95.00 美元，并对该股票设定了 “市场表现优于大盘” 的评级。一位研究分析师给予该股票 “强烈买入” 评级，八位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Crinetics Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 76.50 美元。</p>
</div><p><strong>Get Our Latest Analysis on CRNX</strong></p>
<div class="lb-trans"><p><strong>获取我们对 CRNX 的最新分析</strong></p>
</div><h2>Crinetics Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 股票表现</h2>
</div><p>Shares of CRNX opened at $37.48 on Monday. The business's fifty day moving average price is $38.41 and its two-hundred day moving average price is $43.89. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -7.31 and a beta of 0.28. Crinetics Pharmaceuticals has a 52 week low of $25.83 and a 52 week high of $57.99.</p>
<div class="lb-trans"><p>CRNX 的股票在周一开盘价为 37.48 美元。该公司的 50 日移动平均价格为 38.41 美元，200 日移动平均价格为 43.89 美元。该公司的市值为 39.5 亿美元，市盈率为 -7.31，贝塔值为 0.28。Crinetics Pharmaceuticals 的 52 周低点为 25.83 美元，52 周高点为 57.99 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Crinetics Pharmaceuticals news, CEO Richard Scott Struthers sold 21,981 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief executive officer owned 404,778 shares of the company's stock, valued at approximately $15,126,553.86. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeff E. Knight sold 85,163 shares of the firm's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $40.10, for a total value of $3,415,036.30. Following the transaction, the insider owned 105,289 shares in the company, valued at approximately $4,222,088.90. This trade represents a 44.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 142,380 shares of company stock worth $5,569,475 over the last three months. Insiders own 3.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Crinetics Pharmaceuticals 的新闻中，首席执行官 Richard Scott Struthers 于 3 月 16 日星期一出售了 21,981 股该股票。该股票以平均价格 37.37 美元出售，总价值为 821,429.97 美元。交易后，首席执行官持有该公司 404,778 股股票，价值约为 15,126,553.86 美元。这代表了他们持股比例的 5.15% 的减少。该交易在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。此外，内部人士 Jeff E. Knight 于 4 月 8 日星期三出售了 85,163 股该公司的股票。该股票以平均价格 40.10 美元出售，总价值为 3,415,036.30 美元。交易后，内部人士持有该公司 105,289 股股票，价值约为 4,222,088.90 美元。这笔交易代表了他们持股比例的 44.72% 的减少。该销售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内出售了价值 5,569,475 美元的 142,380 股公司股票。内部人士持有该公司 3.80% 的股票。</p>
</div><h2>Institutional Trading of Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>Crinetics Pharmaceuticals 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Crinetics Pharmaceuticals by 55.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 852,258 shares of the company's stock valued at $30,935,000 after acquiring an additional 303,281 shares during the period. SEB Asset Management AB acquired a new position in Crinetics Pharmaceuticals during the first quarter valued at approximately $7,769,000. Principal Financial Group Inc. increased its stake in Crinetics Pharmaceuticals by 32.3% in the first quarter. Principal Financial Group Inc. now owns 7,066 shares of the company's stock valued at $257,000 after purchasing an additional 1,725 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in Crinetics Pharmaceuticals by 4.0% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 28,477 shares of the company's stock valued at $1,034,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in Crinetics Pharmaceuticals in the first quarter worth $126,000. 98.51% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近修改了对该股票的持有。Dimensional Fund Advisors LP 在第一季度将其在 Crinetics Pharmaceuticals 的持仓增加了 55.2%。Dimensional Fund Advisors LP 现在拥有 852,258 股该公司的股票，价值 30,935,000 美元，在此期间又收购了 303,281 股。SEB Asset Management AB 在第一季度收购了 Crinetics Pharmaceuticals 的新头寸，价值约为 7,769,000 美元。Principal Financial Group Inc. 在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 32.3%。Principal Financial Group Inc. 现在拥有 7,066 股该公司的股票，价值 257,000 美元，在上个季度又购买了 1,725 股。肯塔基州教师退休系统在第一季度将其在 Crinetics Pharmaceuticals 的持股增加了 4.0%。肯塔基州教师退休系统现在拥有 28,477 股该公司的股票，价值 1,034,000 美元，在上个季度又购买了 1,100 股。最后，Fifth Third Bancorp 在第一季度收购了 Crinetics Pharmaceuticals 的新股份，价值 126,000 美元。98.51% 的股票由机构投资者持有。</p>
</div><h2>About Crinetics Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Crinetics Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于发现、开发和商业化用于治疗罕见内分泌疾病的新型治疗药物。该公司的专有平台利用对激素受体信号传导的洞察，设计小分子候选药物，以解决由激素活动失调引起的疾病。Crinetics 的研究工作集中在针对生长抑素、抗利尿激素和其他 GPCR 介导的通路，旨在改善患者的便利性和依从性。</p>
</div><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 paltusotine（前称 CRN04777）是一种选择性非肽类生长抑素受体 2 型激动剂，正在评估用于治疗肢端肥大症和类癌综合症腹泻。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Crinetics Pharmaceuticals</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Crinetics Pharmaceuticals 更好的股票</li>
<li>超越 NVIDIA：强劲势头的 AI 相关投资机会</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后获得提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将从这项重大法案中受益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRNX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Crinetics Pharmaceuticals 吗？</h2>
</div><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Crinetics Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Crinetics Pharmaceuticals 并不在名单上。</p>
</div><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Crinetics Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Crinetics Pharmaceuticals 2030 财年的收益预估为负